image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 8.645
-1.51 %
$ 10.1 B
Market Cap
-2.66
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one VTRS stock under the worst case scenario is HIDDEN Compared to the current market price of 8.64 USD, Viatris Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one VTRS stock under the base case scenario is HIDDEN Compared to the current market price of 8.64 USD, Viatris Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one VTRS stock under the best case scenario is HIDDEN Compared to the current market price of 8.64 USD, Viatris Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart VTRS

image
$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
14.7 B REVENUE
-4.46%
10.1 M OPERATING INCOME
-98.68%
-634 M NET INCOME
-1159.41%
2.3 B OPERATING CASH FLOW
-17.74%
1.8 B INVESTING CASH FLOW
335.66%
-4.33 B FINANCING CASH FLOW
-88.12%
3.25 B REVENUE
-7.76%
-2.88 B OPERATING INCOME
-1503.00%
-3.04 B NET INCOME
-488.96%
536 M OPERATING CASH FLOW
10.94%
-65.1 M INVESTING CASH FLOW
61.41%
-467 M FINANCING CASH FLOW
67.12%
Balance Sheet Viatris Inc.
image
Current Assets 9.52 B
Cash & Short-Term Investments 1.09 B
Receivables 3.52 B
Other Current Assets 4.91 B
Non-Current Assets 32 B
Long-Term Investments 1.35 B
PP&E 2.67 B
Other Non-Current Assets 28 B
8.49 %11.83 %3.25 %6.42 %67.38 %Total Assets$41.5b
Current Liabilities 5.78 B
Accounts Payable 1.36 B
Short-Term Debt 95.4 M
Other Current Liabilities 4.33 B
Non-Current Liabilities 17.1 B
Long-Term Debt 14.2 B
Other Non-Current Liabilities 2.87 B
5.93 %18.93 %62.18 %12.54 %Total Liabilities$22.9b
EFFICIENCY
Earnings Waterfall Viatris Inc.
image
Revenue 14.7 B
Cost Of Revenue 9.12 B
Gross Profit 5.62 B
Operating Expenses 5.61 B
Operating Income 10.1 M
Other Expenses 644 M
Net Income -634 M
16b16b14b14b12b12b10b10b8b8b6b6b4b4b2b2b00(2b)(2b)15b(9b)6b(6b)10m(644m)(634m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
38.15% GROSS MARGIN
38.15%
0.07% OPERATING MARGIN
0.07%
-4.30% NET MARGIN
-4.30%
-3.40% ROE
-3.40%
-1.53% ROA
-1.53%
0.03% ROIC
0.03%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Viatris Inc.
image
3b3b3b3b2b2b2b2b1b1b500m500m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -634 M
Depreciation & Amortization 2.89 B
Capital Expenditures -326 M
Stock-Based Compensation 146 M
Change in Working Capital 0
Others 984 M
Free Cash Flow 1.98 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Viatris Inc.
image
Wall Street analysts predict an average 1-year price target for VTRS of $13.3 , with forecasts ranging from a low of $10 to a high of $15 .
VTRS Lowest Price Target Wall Street Target
10 USD 15.67%
VTRS Average Price Target Wall Street Target
13.3 USD 54.23%
VTRS Highest Price Target Wall Street Target
15 USD 73.51%
Price
Max Price Target
Min Price Target
Average Price Target
151514141313121211111010998877Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
1.38% DIVIDEND YIELD
0.12 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.500.500.450.450.400.400.350.350.300.300.250.250.200.200.150.150.100.100.050.050.000.000.120.120.120.120.110.120.120.120.120.110.120.120.120.110.450.120.480.120.480.120.480.122021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Viatris Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
2.68 M USD 2
9-12 MONTHS
8.31 M USD 1
Bought
536 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference Transcript Viatris Inc. (NASDAQ:VTRS ) Jefferies Global Healthcare Conference June 5, 2025 8:10 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Theodora Mistras - Chief Financial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Yuchen Ding Good morning, and welcome to the day 2 of the Jefferies Healthcare Conference. seekingalpha.com - 1 week ago
Viatris Deadline Today: Rosen Law Firm Urges Viatris Inc. (NASDAQ: VTRS) Stockholders With Large Losses to Contact the Firm for Information About Their Rights NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025, both dates inclusive (the “Class Period”). Viatris describes itself as a “global healthcare company, which engages in the provision of healthcare and pharmaceutical products.” For more information, submit a form, email attorney Phillip Kim, or give us a call. businesswire.com - 1 week ago
VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm LOS ANGELES--(BUSINESS WIRE)--VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm. businesswire.com - 1 week ago
Class Action Filed Against Viatris Inc. (VTRS) Over Securities Violations - Contact Levi & Korsinsky Today NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=151471&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
DEADLINE ALERT for VTRS and CGC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. globenewswire.com - 1 week ago
Class Action Lawsuit Filed: Viatris Inc. (VTRS) - Join by June 3, 2025 - Contact Levi & Korsinsky NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=151460&wire=1&utm_campaign=8 or contact Joseph E. Levi, Esq. accessnewswire.com - 2 weeks ago
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Viatris Inc. (VTRS) NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=151437&wire=1&utm_campaign=24 or contact Joseph E. Levi, Esq. accessnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in Viatris Inc. of Class Action Lawsuit And Upcoming Deadlines - VTRS NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. ("Viatris" or the "Company") (NASDAQ:VTRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. accessnewswire.com - 2 weeks ago
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Viatris Inc. (VTRS) Investors of June 3, 2025 Deadline NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=151411&wire=1&utm_campaign=16 or contact Joseph E. Levi, Esq. accessnewswire.com - 2 weeks ago
Levi & Korsinsky Urges Viatris (VTRS) Shareholders to Act Before Lead Plaintiff Deadline June 3, 2025 NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=151395&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq. accessnewswire.com - 2 weeks ago
FINAL REMINDER VTRS DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Viatris Inc. Investors to Participate in the Class Action Lawsuit NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Viatris Inc. ("Viatris" or "the Company") (NASDAQ:VTRS) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Viatris securities between August 8, 2024 and February 26, 2025, both dates inclusive (the "Class Period"). accessnewswire.com - 2 weeks ago
8. Profile Summary

Viatris Inc. VTRS

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 10.1 B
Dividend Yield 1.38%
Description Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Contact 1000 Mylan Boulevard, Canonsburg, PA, 15317 https://www.viatris.com
IPO Date March 17, 1980
Employees 32000
Officers Mr. Paul B. Campbell Chief Accounting Officer, Senior Vice President & Corporate Controller Ms. Lara Ramsburg Chief Corporate Affairs Officer Dr. Corinne M. Le Goff M.B.A., Pharm.D. Chief Commercial Officer Mr. Ramkumar V. Rayapureddy Chief Information Officer Mr. Menassie Taddese M.B.A. President of Emerging Markets Ms. Theodora Mistras Chief Financial Officer Mr. Brian S. Roman Chief Legal Officer Mr. Andrew Enrietti Chief People Officer Mr. Scott Andrew Smith Ph.D. Chief Executive Officer & Director Mr. Derek Glover Chief Quality Officer